FOLD - Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.
Digital Poster Presentations:
- Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amenable GLA variants
- Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australia
- Incidence and prevalence of newborn, paediatric, and adolescent patients with Fabry disease: a targeted literature review
- Presenter: Ian Keyzor, Amicus Therapeutics, Marlow, United Kingdom
The posters can be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .
For more information on the International Congress of Inborn Errors of Metabolism 2021, please visit www.iciem2021.com.au .
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com , and follow us on Twitter and LinkedIn .
CONTACT:
Investors :
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media :
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G